John Porter, MBBS PhD - Chief Medical Officer
John Porter is Chief Medical Officer at Diurnal. John is a paediatric endocrinologist and has 10 years’ experience in the pharmaceutical industry. Previously, John had medical director roles at Pfizer, Novartis and GSK covering a wide portfolio of medicines in therapy areas including endocrinology, haematology, infectious disease and vaccines. John studied medicine at Oxford and Newcastle-upon-Tyne Universities, qualifying in 1995. He trained in paediatric endocrinology and diabetes and has a PhD in the genetics of paediatric diabetes.... Show more Stewart Jones - Operations Director
Stewart has over 25 years’ experience in CMC and programme management, spanning the fine chemicals, CMO, Biotech and BioPharmaceutical industries. Stewart’s responsibility is to ensure that all of Diurnal’s development programmes are fully integrated and to manage their progress through to successful conclusion. Prior to joining Diurnal, Stewart was at AIM listed Mereo BioPharma as Head of CMC and oversaw all manufacturing activities. Before Mereo, Stewart was at Chroma Therapeutics for over 9 years and was responsible for the development of the clinical portfolio, all of which have been successfully licensed on. Previously Stewart worked in the development department at Evotec (now Aptuit) for 9 years leading teams on the manufacturing development of several different therapeutic entities from small molecules to large molecules, peptides and liquid crystals, some of which have subsequently gone on to commercial launch. Stewart has a BSc (hons) in chemistry.... Show more Dr Tim Tasker BA MBBS FRCP(UK) - VP Clinical Development
Tim is VP Clinical Development responsible for First in Human Clinical Studies and Experimental Medicine Studies of new medicines from the Neurocrine portfolio which are conducted in the UK and Europe. Tim was previously the Chief Medical Officer of Sosei Heptares , and its predecessor Heptares, from 2014 to 2022 where he established the clinical development function and was responsible for the Clinical Development of the selective muscarinic agonist portfolio licensed by Neurocrine in 2021. He has over 35 years experience in clinical development predominantly in Phases I and II with a predominant focus in the Neurosciences . He held a number of roles in Clinical Pharmacology over a 25yr plus career in GSK and its predecessor companies including VP of Clinical Units with global responsibility for all of GSK’s internal clinical pharmacology units in UK, US, Europe and Australia , including the establishment of GSK’s Experimental Medicine Centre in Addenbrooke’s Hospital Cambridge UK. He has also held development leadership roles in Evotec and established a successful Early Development Consulting Company in Australia and Asia Pacific... Show more 
